Target type: cellularcomponent
A type of plasma membrane that has been modified through addition of distinct intracellular and extracellular components, including ceramide, found in cornifying epithelial cells (corneocytes). [GOC:add, PMID:11112355, PMID:11590230, PMID:15803139]
The cornified envelope (CE) is a specialized, highly cross-linked protein structure that forms the outermost layer of the stratum corneum in vertebrate skin. It provides a barrier against environmental insults and contributes to the skin's mechanical strength. The cellular component of the CE is a complex mixture of proteins, primarily cytokeratins, cross-linked by transglutaminase enzymes. The major cytokeratins involved in CE formation are cytokeratins 1 and 10, which are expressed in the upper layers of the epidermis and are specifically upregulated in differentiating keratinocytes. These cytokeratins are synthesized as precursors, which are then processed and assembled into intermediate filaments. During the terminal differentiation of keratinocytes, the intermediate filaments undergo extensive cross-linking through the action of transglutaminases, primarily transglutaminase 1 (TG1). TG1 is a calcium-dependent enzyme that catalyzes the formation of isopeptide bonds between specific lysine and glutamine residues in the cytokeratins, leading to the formation of a rigid, insoluble network. In addition to cytokeratins, other proteins have been found to be incorporated into the CE, including loricrin, involucrin, and small proline-rich proteins (SPRRs). These proteins contribute to the structural integrity and barrier function of the CE. The formation of the CE is a tightly regulated process that is essential for skin barrier function. Defects in CE formation can lead to skin disorders, such as ichthyosis and epidermolytic hyperkeratosis. The CE is a unique and complex cellular component that plays a critical role in skin biology.'
"
Protein | Definition | Taxonomy |
---|---|---|
Kallikrein-6 | A kallikrein-6 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q92876] | Homo sapiens (human) |
Kallikrein-7 | A kallikrein-7 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P49862] | Homo sapiens (human) |
Caspase-14 | A caspase-14 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P31944] | Homo sapiens (human) |
Calpain-1 catalytic subunit | A calpain-1 catalytic subunit that is encoded in the genome of human. [PRO:DNx, UniProtKB:P07384] | Homo sapiens (human) |
Annexin A2 | An annexin A2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P07355] | Homo sapiens (human) |
Heat shock protein beta-1 | A heat shock protein beta-1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P04792] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
isoquinoline-1,3,4-trione | isoquinoline-1,3,4-trione: structure in first source | ||
aloxistatin | aloxistatin : An L-leucine derivative that is the amide obtained by formal condensation of the carboxy group of (2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid with the amino group of N-(3-methylbutyl)-L-leucinamide. aloxistatin: a membrane-permeable cysteine protease inhibitor | epoxide; ethyl ester; L-leucine derivative; monocarboxylic acid amide | anticoronaviral agent; cathepsin B inhibitor |
carbobenzoxyvalylphenylalanine aldehyde | Z-Val-Phe-H : A dipeptide resulting from the formal condensation of the carboxy group of N-benzyloxycarbonyl-L-valine with the amino group of L-phenylalanine aldehyde. It is a potent cell-permeable inhibitor of calpain I and II, and is also a gamma-secretase inhibitor. | aldehyde; carbamate ester; dipeptide | antileishmanial agent; apoptosis inhibitor; EC 3.4.22.52 (calpain-1) inhibitor; EC 3.4.22.53 (calpain-2) inhibitor; EC 3.4.23.46 (memapsin 2) inhibitor |
calpeptin | amino acid amide | ||
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine | N-(N-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine: inhibits calcium-activated neutral protease; see also record for E-64; RN given refers to (2-S-(2alpha,3beta)(R*)-isomer) | leucine derivative | |
e 64 | E 64: cysteine protease inhibitor of microbial origin, which inhibits cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.-) | dicarboxylic acid monoamide; epoxy monocarboxylic acid; guanidines; L-leucine derivative; zwitterion | antimalarial; antiparasitic agent; protease inhibitor |
birb 796 | aromatic ether; morpholines; naphthalenes; pyrazoles; ureas | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator | |
acetylleucyl-leucyl-norleucinal | acetylleucyl-leucyl-norleucinal : A tripeptide composed of N-acetylleucyl, leucyl and norleucinal residues joined in sequence. acetylleucyl-leucyl-norleucinal: a proteasome inhibitor | aldehyde; tripeptide | cysteine protease inhibitor |
N-(3,4-dimethylphenyl)-2-[[5-[[(4,6-dimethyl-2-pyrimidinyl)thio]methyl]-4-(2-furanylmethyl)-1,2,4-triazol-3-yl]thio]acetamide | anilide | ||
benzyloxycarbonyl-phe-ala-fluormethylketone | cathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1). | ||
3-deoxysappanchalcone | 2'-O-methylisoliquiritigenin : A member of the class of chalcones that is isoliquiritigenin in which one of the hydroxy groups at position 2' is replaced by a methoxy group. 3-deoxysappanchalcone: Anti-allergic from the roots and heartwood of Caesalpinia sappan; structure in first source | chalcones; monomethoxybenzene; phenols | metabolite |
paepalantine | paepalantine: an isocoumarin from Paepalanthus vellozioides; structure given in first source | ||
gabexate methanesulfonate | benzoate ester; guanidines; methanesulfonate salt | ||
snj-1945 | ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester: calpain inhibitor | ||
phenylalanyl-valine | Val-Phe : A dipeptide formed from L-valine and L-phenylalanine residues. | dipeptide | metabolite |
ca 074 | |||
a-705253 | A-705253: structure in first source | ||
sb 242235 | SB 242235: p38 MAP kinase antagonist | ||
sja 6017 | N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal: structure in first source | ||
rpr 120844 | |||
phevalin | phevalin : A member of the class of pyrazinones that is pyrazin-2(1H)-one substituted by an isopropyl and benzyl groups at position 3 and 6, respectively. It is a natural product found in Staphylococcus aureus that inhibits calpain in a casein hydrolysis assay (IC50 = 1.3 muM), contributes to S. aureus infection in mice, and alters human keratinocyte gene expression. phevalin: isolated from a Streptomyces sp.; structure given in first source | benzenes; pyrazinone | bacterial metabolite; calpain inhibitor |
calpain inhibitor iii | calpain inhibitor III: potential anticataract drug | ||
PF-00835231 | PF-00835231 : A primary alcohol resulting from the cleavage of the phosphate group of the prodrug PF-07304814. It is an inhibitor of SARS-CoV-1 and -2 main protease (3CLpro) and exhibits potent in vitro antiviral activity. | aromatic ether; indolecarboxamide; L-leucine derivative; primary alcohol; pyrrolidin-2-ones; secondary carboxamide | anticoronaviral agent; drug metabolite; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor |
N-cyclopropyl-3-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-4-methylbenzamide | N-cyclopropyl-3-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-4-methylbenzamide : A dicarboxylic acid diamide obtained by condensation of the 3- and 4'-carboxy groups of 6-methyl[1,1'-biphenyl]-3,4'-dicarboxylic acid with cyclpropylamine and cyclpropylmethylamine respectively. | benzamides; biphenyls; cyclopropanes; dicarboxylic acid diamide | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor |
grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source | ||
skepinone-l | skepinone-L: a dibenzosuberone-type p38 MAPK inhibitor; structure in first source | ||
nsc751382 | |||
MK-8353 | MK-8353 : A member of the class of indazoles that is 1H-indazole substituted by a 6-(propan-2-yloxy)pyridin-3-yl group at position 3 and by a {[(3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)pyrrolidin-3-yl]carbonyl}amino group at position 5. It is a potent and selective inhibitor of ERK1 and ERK2 in vitro (IC50 values of 23.0 nM and 8.8 nM, respectively). The drug is being developed by Merck Sharp & Dohme and is currently in clinical development for the treatment of advanced/metastatic solid tumors. MK-8353: ERK inhibitor used in oncology | aromatic ether; dihydropyridine; indazoles; methyl sulfide; N-alkylpyrrolidine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; triazoles | antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor |
N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide | N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 1H-indole-2-carboxylic acid with the primary amino group of 3-cyclohexyl-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-alaninamide. It is an inhibitor of SARS coronavirus main proteinase and inhibits SARS-CoV-2 replication in cell culture (EC50 = 0.53 muM). | aldehyde; indolecarboxamide; oligopeptide; pyrrolidin-2-ones; secondary carboxamide | anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor |